BridgeBio Pharma Reports Strong 2025 Revenue and Operational Update at J.P. Morgan Conference
BridgeBio Pharma announced preliminary Q4 2025 revenue of $146 million and full-year product revenue of $362.4 million at the J.P. Morgan Healthcare Conference, with Truist raising its price target earlier in the week.